In recent years, with the deepening study on the pathogenesis of psoriasis, the important role of interleukin-23 (IL-23)/IL-17 axis in promoting the occurrence and continuation of psoriasis has attracted more and more attention and the studies on the development of IL-23 inhibitors and IL-17 inhibitors and their clinical application are also being carried out continuously. This evidence concerns the gene IL37 and psoriasis.